CBD for pain relief
CBD for pain relief is currently at the heart of medical, scientific, and public discussions. In 2025, data is becoming clearer, clinical trials are multiplying, and consumers are looking for natural solutions to relieve their chronic pain. But what does recent science really say? Which products are effective? And above all, how can we distinguish what is proven from what is just marketing? This article reviews the latest 2025 studies, validated medical uses, and best practices for creating credible and engaging content on this topic.
Latest scientific advances on CBD and pain in 2025
A significant clinical trial: VER‑01 and chronic lower back pain
On September 29, 2025, Sciences et Avenir reported the results of a Phase 3 trial on a cannabis extract called VER‑01. More than 800 patients suffering from refractory chronic low back pain participated in this controlled and randomized study. Result: an average pain reduction of 1.9 points compared to 0.6 for the placebo after 12 weeks. The benefits were maintained for up to 12 months, with improved sleep and mobility.
But be careful: VER‑01 contains 2.5 mg of THC per dose. It is therefore not a classic over-the-counter CBD product, but a pharmaceutical extract developed for medical use. This distinction is essential to avoid misleading readers or customers.
Expert reactions and important nuances
Specialized media such as Fréquence Médicale and TF1 Info reported these results, emphasizing that this type of therapeutic cannabis cannot be compared to CBD products sold in stores or online. Experts insist on the necessary vigilance regarding the risks of long-term addiction, which are still poorly documented.
The French framework: medical experimentation and monitoring by the ANSM
In June 2025, the ANSM published a follow-up document on the French experiment with medical cannabis. More than 1000 patients suffering from refractory neuropathic pain were monitored, with detailed data on side effects and serious cases. This report is a valuable resource for any content targeting France or addressing the regulations in force in 2025.
Over-the-counter CBD: what does 2025 data say?
Promising but nuanced effects
An article by DSM‑Firmenich summarizes several clinical trials conducted in 2025 on oral CBD. Result: at least five studies show an improvement in pain. However, it is crucial to distinguish CBD-rich extracts from THC-containing products, as the mechanisms of action and effects are not identical.
Research on brain inflammation
Work carried out in France, particularly at the ICM, suggests that CBD could play a role in modulating brain inflammation — a key factor in certain chronic pains. This research, relayed by Chanvrery, opens the way for new therapeutic applications, particularly for neuroinflammatory pain.
Which CBD products are recommended for pain in 2025?
Comparisons and consumer guides
The OrigineCBD website offers a guide to the best CBD products for pain in 2025. Oils, capsules, topical balms: the most popular forms are scrutinized, with advice on dosages and complementary ingredients such as arnica or devil's claw. This type of content is ideal for conversion pages or product sheets.
Practical use and feedback
Blogs like CBDE.fr compile user feedback, usage tips (oral, cutaneous), and frequently asked questions. This content is valuable for structuring an effective FAQ and addressing consumer concerns in a reassuring and documented manner.
Frequently asked questions in December 2025
Are over-the-counter CBD products as effective as VER‑01?
No. The VER‑01 trial focused on an extract containing 2.5 mg of THC, which fundamentally distinguishes it from classic CBD products. The observed effects cannot be generalized to THC-free oils or capsules.
Can CBD replace opioids?
Not yet. While some results are promising, no study has yet validated a generalized substitution. Long-term trials are needed to confirm this hypothesis.
What are the known side effects in 2025?
The ANSM reports adverse effects within the framework of the French experiment, including some serious cases. Medical monitoring remains essential for any therapeutic use.
What is the most effective form?
It depends on the indication. Trials use standardized formulations. For general public products, it is recommended to follow the manufacturer's advice or consult a healthcare professional. You can also consult our article on buying CBD in pharmacies.
Tips for creating content that converts
- Distinguish between wellness CBD and medical extracts containing THC.
- Use numerical data from 2025 studies to support your arguments.
- Structure your pages with a clear FAQ, anchored in current concerns.
- Adapt your formats to popular uses: oils, capsules, balms.
- Highlight French regulations to reassure readers.
Also read
In December 2025, facing the rise of chronic pain and the search for natural alternatives to conventional medicines, one question constantly resurfaces in search engines: what is the best CBD for pain relief? This question, shared by thousands of people, reflects an urgent need for effective, non-addictive, and accessible solutions. In this article, we will explore the answers to the most frequently asked questions about CBD for pain relief, based on recent trends, product innovations, and concrete user feedback.
What is the best CBD for pain relief in 2025?
In 2025, the CBD market has become considerably more refined. We no longer just talk about oil or capsules, but about targeted formulations, designed for specific pains. The best product therefore depends on the type of pain, its frequency, and its intensity.
For muscle and joint pain
Heating creams based on CBD (1000 mg) and arnica are highly favored. They act quickly, especially after physical exertion or in cases of muscle soreness. Their soothing effect is enhanced by the heat and local penetration of CBD. This type of product is recommended for athletes or people suffering from muscle tension related to stress or poor posture.
A highly sought-after product example: transdermal patches with prolonged release (8 to 24 hours), ideal for localized chronic pain. These patches are often enriched with CBG or arnica, and are available in pharmacies or specialized stores.
For chronic pain (arthritis, neuropathies)
Full-spectrum CBD remains a benchmark. Combined with other cannabinoids such as CBG or CBN, it offers a powerful entourage effect. In 2025, microdosed capsules (2 to 5 mg), often enriched with adaptogens, are preferred by regular users, especially active urban dwellers.
To learn more on this topic, discover our dedicated article: CBD and pharmacy: what formulations in 2025?
CBD or Cannabielsoxa: which to choose for chronic pain?
The rise of Cannabielsoxa in 2025 has reshuffled the cards. This non-psychoactive cannabinoid, little known to the general public a year ago, is now presented as a credible alternative to CBD, especially for deep inflammatory pain.
Why is Cannabielsoxa increasingly appealing?
It acts on TRPV1 receptors, involved in modulating pain and inflammation, without inducing tolerance. In other words, its effectiveness does not decrease over time, unlike some CBD-based products. It is often used in a combined formulation with CBD or CBG to enhance its action.
To better understand this molecule, you can consult this reference article: Cannabielsoxa, the new star of cannabinoids?
Are CBD patches effective for muscle pain?
The answer is yes, but not all patches. In 2025, the most effective ones combine a high concentration of CBD (at least 50 mg per patch), slow release (up to 24 hours), and synergistic agents like arnica or camphor. These patches are particularly useful for lower back pain, neck pain, or tendinitis.
Advantages of transdermal patches
- Continuous release of CBD
- Simple and discreet application
- Fewer digestive side effects than with oils or capsules
Users also appreciate their practical side: a patch in the morning, and the pain is managed all day. Feedback is very positive, especially for active people or those on the go.
CBD-CBG combinations: a promising anti-inflammatory synergy
The CBD-CBG duo is establishing itself as a benchmark for inflammatory pain, particularly in cases of arthritis or rheumatism. CBG, often called the "mother cannabinoid," acts in conjunction with CBD to soothe inflamed tissues and reduce burning or stiffness sensations.
Recommended products in 2025
- 1:1 CBD-CBG sublingual oils
- Topical creams enriched with CBG
- Combined capsules with adaptogens (ashwagandha, rhodiola)
A very comprehensive article on this subject is available here: CBD and inflammation: what advances in 2025?
What behaviors after finding the information?
Once informed, consumers quickly take action. In 2025, purchasing behaviors have evolved:
- Testing new products in stores or pharmacies
- Creating monthly wellness baskets
- Seeking personalized advice (dosage, frequency, interactions)
"Boosted" CBD flowers for rapid effect, or CBN-based formulations for sleep and pain, are in high demand. For an overview of new products, consult this selection: New CBD products to try in 2025
Most frequent doubts and objections in December 2025
Despite the enthusiasm, several questions remain:
- Real effectiveness: clinical studies are still ongoing, although user feedback is very positive
- Side effects: rare but possible at high doses (fatigue, dry mouth)
- Legality: products must contain less than 0.3% THC to be authorized in France
To follow legislative developments, particularly concerning medical cannabis, this file is up to date: Medical cannabis in France in 2025
Beginners or experts: distinct profiles
In 2025, the market has segmented. Beginners look for easy-to-use products: creams, low-dose oils, infusions. Experts, on the other hand, explore rarer cannabinoids like Cannabielsoxa or CPR, often in full spectrum.
Microdoses appeal to active urban dwellers, who want to relieve tension without affecting their concentration or energy. This phenomenon is well documented in our article: Modern phytotherapy and CBD
Related searches in December 2025
Here are the most frequent queries this month:
- "Cannabielsoxa vs CBD pain"
- "Best CBD patches 2025"
- "CBG anti-inflammatory arthritis"
- "CBD pharmacy office"
- "CBN+CBD sleep and pain"
These searches show a growing interest in combined products and personalized solutions. For a broader analysis, read: CBD market in 2025: situation report
New concerns since September 2025
Since the start of the academic year, several strong trends have emerged:
- Growing popularity of Cannabielsoxa for its zero tolerance
- Multi-cannabinoid formulations (CBD-CBG-Cannabielsoxa)
- Patches personalized according to pain profile
- Uncertainty about the accessibility of medical cannabis after 2025
To learn more about future prospects, explore our complete analysis: The future of medical cannabis in France
Leave a comment